 | Up a level |
Geyer, C. E., Jr., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmana, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S. M., Eisen, A., Elsafy, F., Fein, L. E., Fielding, A., Ford, J. M., Friedman, S., Gelmon, K. A., Gianni, L., Gnant, M., Hollingsworth, S. J., Im, S-A, Jager, A., Lakhani, S. R., Janni, W., Linderholm, B., Liu, T-W, Loman, N., Korde, L., Loibl, S., Lucas, P. C., Marme, F., de Duenas, E. Martinez, McConnell, R., Phillips, K-A, Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C. F., Spanic, T., Stickeler, E., Toi, M., Traina, T. A., Viale, G., Zoppoli, G., Park, Y. H., Yerushalmi, R., Yang, H., Pang, D., Jung, K. H., Mailliez, A., Fan, Z., Tennevet, I, Zhang, J., Nagy, T., Sonke, G. S., Sun, Q., Parton, M., Colleoni, M. A., Schmidt, M., Brufsky, A. M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., Tutt, A. N. J. and Johannsson, O. Th (2022). Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann. Oncol., 33 (12). S. 1250 - 1269. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Harter, P., Baumann, K., Heimbach, A., Reuss, A., Jackisch, C., Hauke, J., Park-Simon, T. W., Richters, L., Hanker, L., Kroeber, S., Pfisterer, J., Gevensleben, H., Schnelzer, A., Dietrich, D., Schneider, S., Kommoss, S., Marme, F., Prieske, K., Schmutzler, R. and Hahnen, E. (2016). Mutations of risk genes for ovarian cancer in consecutive ovarian cancer patients (AGO TR-1 study). Int. J. Gynecol. Cancer, 26. S. 81 - 83. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438
Heitz, F., Weber-Lassalle, K., Ernst, C., Moellenhoff, K., De Gregorio, N., Hauke, J., Dietrich, D., Borde, J., Jackisch, C., Park-Simon, T-W, Hanker, L. C., Pohl-Rescigno, E., Prieske, K., Kommoss, S., Marme, F., Stingl, J. C., Rita, S., Harter, P. and Hahnen, E. (2022). Chemotherapy-induced mutations in genes of clonal hematopoiesis increase the risk of myeloid neoplasms. Geburtshilfe Frauenheilkd., 82 (10). S. E88 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Llop-Guevara, A., Loibl, S., Villacampa, G., Vladimirova, V., Schneeweiss, A., Karn, T., Zahm, D. -m., Herencia-Ropero, A., Jank, P., van Mackelenbergh, M., Fasching, P. A., Marme, F., Stickeler, E., Schem, C., Dienstmann, R., Florian, S., Nekljudova, V., Balmana, J., Hahnen, E., Denkert, C. and Serra, V. (2021). Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann. Oncol., 32 (12). S. 1590 - 1597. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J. and Loibl, S. (2021). Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. Ann. Oncol., 32. S. S443 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Marme, F., Harter, P., Hauke, J., Heitz, F., Reuss, A., Kommoss, S., Heimbach, A., Prieske, K., Richters, L., Burges, A., Neidhardt, G., de Gregorio, N., El-Balat, A., Hilpert, F., Meier, W., Heubner, M., Kast, K., Braicu, I., Hahnen, E. and Schmutzler, R. (2016). Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). Int. J. Gynecol. Cancer, 26. S. 194 - 196. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438
Marme, F., Schneeweiss, A., Aigner, J., Eidt, S., Altevogt, P., Sinn, P. and Wirtz, R. M. (2012). Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Richters, L., Schouten, P. C., Park-Simon, T-W., Hauke, J., Hanker, L., Dietrich, D., Pfisterer, J., Krockenberger, M., Kluin, R., Schnelzer, A., du Bois, A., Kommoss, S., Heimbach, A., Schmidt, S., Marme, F., Prieske, K., Linn, S. C., Schmutzler, R. K., Harter, P. and Hahnen, E. (2018). BRCA-like classification in ovarian cancer - Results from the AGO-TR1-trial. Oncol. Res. Treat., 41. S. 85 - 86. BASEL: KARGER. ISSN 2296-5262
Wirtz, R. M., Aigner, J., Marme, F., Eidt, S., Altevogt, P., Sinn, P. and Schneeweiss, A. (2013). High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Wirtz, R. M., Scheffen, I., Marme, F., Laible, M., Sclombs, K., Schumacher, C., Schneeweiss, A., Eidt, S. and Sinn, H-P (2017). Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445